Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Diabetic patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2) are at particular cardiovascular risk. Fenofibrate’s safety in these patients is an issue because it may elevate plasma creatinine. Furthermore, guidelines regarding fenofibrate dosing in renal impairment vary internationally. We investigated fenofibrate’s effects on cardiovascular and end-stage renal disease (ESRD) events, according to eGFR, in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. RESEARCH DESIGN AND METHODS: Type 2 diabetic patients (aged 50–75 years) with eGFR ≥30 mL/min/1.73 m2 were randomly allocated to a fixed dose of fenofibrate (200 mg daily) (n = 4,895) or placebo (n = 4,900) for 5 years. Baseline renal function (Modification of Diet in Renal Disease equation) was grouped by eGFR (30–59, 60–89, and ≥90 mL/min/1.73 m2). The prespecified outcome was total cardiovascular events (composite of cardiovascular death, myocardial infarction, stroke, and coronary/carotid revascularization). Serious adverse events and instances of ESRD (plasma creatinine >400 μmol/L, dialysis, renal transplant, or renal death) were recorded. Analysis was by intention to treat. RESULTS: Overall, fenofibrate reduced total cardiovascular events, compared with placebo (hazard ratio 0.89 [95% CI 0.80–0.99]; P = 0.035). This benefit was not statistically different across eGFR groupings (P = 0.2 for interaction) (eGFR 30–59 mL/min/1.73 m2: 0.68 [0.47–0.97], P = 0.035; eGFR ≥90 mL/min/1.73 m2: 0.85 [0.70–1.02], P = 0.08). ESRD rates were similar between treatment arms, without adverse safety signals of fenofibrate use in renal impairment. CONCLUSIONS: Patients with type 2 diabetes and moderate renal impairment benefit from long-term fenofibrate, without excess drug-related safety concerns compared with those with no or mild renal impairment. Fenofibrate treatment should not be contraindicated in moderate renal impairment, suggesting that current guidelines may be too restrictive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is a known effect of PPAR-α agonists.[27][28][29]”
From A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) · cites this paper as [28]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465 · cited 1×
“Unfortunately, the implementation of established preventive treatment recommendations remains incomplete (24), and even with intensive multifactorial risk reduction, the CVD complication rate in type 2 diabetic patients remains unacceptably high (25).”
Background(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284 · cited 4×
“The rise in plasma creatinine in response to fenofibrate is well documented, but this does not reflect true renal injury or an actual fall in glomerular filtration rate (GFR) (4,7,10).”
BackgroundInfluentialEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Research works printed but not linked: 1
- Laboratoires Fournier, 2004, Fenofibrate Investigator’s Brochure
Cited by
Items 101–118 of 118
Precision Medicine Approaches for Management of Type 2 Diabetes
Chen, D., Fulcher, J., SCOTT, E. S., & Jenkins, A. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_1 · Cited by 3
Self-citationHow Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly
Turgut, F. H., Üstün, İ., & Gökçe, C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0515-7_4
Treatment of DM2 to-day. Should we change priorities? Conclusions based on recent clinical studies
Zilov, A. V. (2009) · Diabetes Mellitus · doi:10.14341/2072-0351-5716
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Little, P. J., Chait, A., Januszewski, A. S., Bobik, A., O'Neal, D. N., & Jenkins, A. J. (2013) · Contemporary diabetes · doi:10.1007/978-1-4614-7554-5_23
Self-citationSimvastatin/fenofibrate combination in the treatment of dyslipidemia: current evidence
Jimenez, J. G., & Haft, G. (2014) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s50952 · Cited by 1
“While there was no significant change in the rates of coronary outcomes, there was however, a slight increase in mortality rates.(123,124) A meta-analysis of RCTs comparing fibrate with placebo illustrated a reduction of major cardiovascular and coronary events by 10% and 13%, respectively.”
Fenofibrate Therapy and Change of Renal Function: Management, What and How?
Kim, S. (2014) · Korean Journal of Medicine · doi:10.3904/kjm.2014.86.6.698
“Fenofibrate 투여가 혈중 크레아티닌 농도를 증가시키고 사구체 여과율을 감소시킨다는 것이 FIELD, ACCORD 연구 에서도 증명되었으며 하위군 분석에서 약제 복용 중단 후 8 주째의 혈중 크레아티닌 농도는 가역적으로 감소하여 대조 군과 유사하게 나타났다[5].”
InfluentialVascular Complications in Diabetes
Dunn, L., Chan, K. H., Ng, M., & Stocker, R. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1428-5_15
Fibrates: Risk Benefits and Role in Treating Dyslipidemias
Jun, M., & Perkovic, V. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_25
“73 m2 [57].”
Diabetes mellitus & disorders of lipid metabolism
Steinmetz, A. (2015) · doi:10.4155/fseb2013.14.200
Fibrates in Chronic Kidney Disease Patients: A Controversial Issue
Baki, A. H., & Zarif, J. K. (2020) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2020.118574
Increased intracellular miR-142 in adults with Type 1 diabetes
Huang, L., Januszewski, A. S., Takahashi, Y., O'Neal, D. N., Ma, J., & Jenkins, A. J. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108597
Self-citationRodrigo, M. D. C. S., & de la Flor, J. C. (2023) · Actualización en Medicina de Familia · doi:10.55783/amf.191102
Gilyarevskiy, S. R. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-304
Chitsazi, M. R., Safari, F., Malekpour, E., Mirzaei, S. A., Shafieyoun, M. H., Golafshan, F., Rouzbahani, H., Nekookhoo, M., Noursina, A., & Siavash, M. (2026) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_441_25
Januszewski, A. S., Huang, M. L., Mangani, A., Ong, K. L., Dalton, C., O’Connell, R. L., Li, L., SULLIVAN, D. R., Strbenac, D., Donoghoe, M. W., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113168
Self-citationLuo, J., Dai, Y., Wu, C., Lan, C., Shi, J., Qi, J., Hua, S., An, Y., Wang, L., Li, P., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1842847
Naim, M. A. A. Z., Thomas, F., Streja, E., Davis, R. L., Kalantar‐Zadeh, K., Sumida, K., & Kovesdy, C. P. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001188
Non-statin Therapies for CKD with Dyslipidemia
Mucsi, I. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0515-7_9
Metadata
- Authors
- Ting, R.-D., Keech, A. C., Drury, P. L., Donoghoe, M. W., Hedley, J., Jenkins, A. J., Davis, T. M. E., Lehto, S., Celermajer, D., Simes, R. J., Rajamani, K., Stanton, K., & on behalf of the FIELD Study Investigators
- Affiliations
- The University of Sydney (AU)
- Auckland Diabetes Centre, Auckland, New Zealand
- Department of Internal Medicine, Wairau Hospital, Blenheim, New Zealand
- The University of Western Australia (AU)
- Kuopio University Hospital (FI)
- Royal Prince Alfred Hospital (AU)
- Royal Perth Hospital (AU)
- Corresponding author
- Ting, Ru-Dee
- Keech, Anthony C.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-01-16
- Volume
- 35
- Issue
- 2
- Pages
- 218-225
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3263870
- OpenAlex
- W2044493153
- Cited by
- 119
- References
- 36
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 9 · 2021: 4 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 10 · 2016: 8 · 2015: 10 · 2014: 12 · 2013: 16 · 2012: 8
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Funders
- European Society of Cardiology
- Cardiac Society of Australia and New Zealand
- Medical Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- fenofibrate, type 2 diabetes, renal dysfunction, estimated glomerular filtration rate, cardiovascular events, end-stage renal disease, serum creatinine, drug safety, lipid-lowering therapy, fieldwork, cardiovascular risk, renal dose adjustment, myocardial infarction, stroke, coronary revascularization, renal death, dialysis, kidney transplantation, cardiovascular mortality, serious adverse events
- MeSH terms
- Aged, Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Male, Middle Aged, Fenofibrate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.